A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

This trial is testing HS-10516, a new oral drug that targets a protein called HIF (hypoxia-inducible factor), in patients with advanced kidney cancer (clear cell renal cell carcinoma) or tumors associated with von Hippel-Lindau (VHL) syndrome — a genetic condition that causes benign and cancerous tumors in the kidneys, brain, spine, and eyes. **You may be eligible if...** - You are 18–80 years old with advanced clear cell kidney cancer or VHL syndrome-associated tumors - Your performance status is good (ECOG 0-1) and you have a life expectancy of at least 12 weeks - You are willing to use contraception during the study **You may NOT be eligible if...** - You have recently received prior HIF inhibitors, chemotherapy, or major surgery (within 4 weeks) - Your blood oxygen is low or you require supplemental oxygen - You have had another cancer (not related to VHL syndrome) - You have a significant bleeding tendency, severe infection, or digestive disease Talk to your doctor to see if this trial is right for you.